References of "Clinical Biochemistry"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study
Van Obbergh, F; Knoops, L; Devos, T et al

in Clinical Biochemistry (2017), 50

This retrospectivemulticenter study in patientswith chronic myeloid leukemia in chronic phasewas undertaken to confirm the clinical relevance of imatinib plasma concentrations monitoring in daily practice ... [more ▼]

This retrospectivemulticenter study in patientswith chronic myeloid leukemia in chronic phasewas undertaken to confirm the clinical relevance of imatinib plasma concentrations monitoring in daily practice. Forty-one patients, with 47 imatinib plasma measurements, were analyzed during treatment with imatinib given at a fixed 400mg daily dose. A significant inverse relationship of imatinib concentration with the patients' weight was observed (Pearson's test: p=0.02,R2=0.1). More interestingly, patientswith poor response (switched to another tyrosine kinase inhibitor because of imatinib failure, or because of disease progression after an initial response) displayed a significantly lower mean imatinib concentration as compared to patients maintained on imatinib (822 ng/mL vs 1099 ng/mL; Student's t-test, p=0.04). Failure or disease progression occurred more often in patients in the lowest quartile of imatinib concentrations compared to patients in the highest quartile (p = 0.02, logrank test). No correlation could be established with other biological or clinical parameter, including complete cytogenic response and majormolecular response. In conclusion: in patients treatedwith imatinib at a fixed daily dose of 400 mg, imatinib plasma concentrations decreased with increasing body weight and were lower in patients switched to another tyrosine kinase inhibitor due to imatinib failure. Systematic determination of imatinib plasma trough levels should be encouraged in such patients. [less ▲]

Detailed reference viewed: 29 (1 ULiège)
Full Text
Peer Reviewed
See detailIdentification and frequencies of cystic fibrosis mutations in central Argentina.
Pepermans, Xavier; Mellado, Soledad; Chialina, Sergio et al

in Clinical biochemistry (2016)

Detailed reference viewed: 70 (5 ULiège)
Full Text
Peer Reviewed
See detailLaboratory challenges in primary aldosteronism screening and diagnosis
Rehan, Muhammad; Raizman, Joshua; CAVALIER, Etienne ULiege et al

in Clinical Biochemistry (2015), 48(6), 377-387

Detailed reference viewed: 46 (7 ULiège)
Full Text
Peer Reviewed
See detailInter-method variability in bone alkaline phosphatase measurement : clinical impact on the management of dialysis patients
CAVALIER, Etienne ULiege; Souberbielle, Jean-Claude; GADISSEUR, Romy ULiege et al

in Clinical Biochemistry (2014), 47(13-14), 1227-30

BACKGROUND: Bone-specific alkaline phosphatase (BAP) is now recommended to assess bone turnover in hemodialysis (HD) patients. However, little is known about potential variability between methods ... [more ▼]

BACKGROUND: Bone-specific alkaline phosphatase (BAP) is now recommended to assess bone turnover in hemodialysis (HD) patients. However, little is known about potential variability between methods available to measure BAP. METHODS: We measured BAP in 76 HD patients with six different assays (Beckman-Coulter Ostase IRMA, Beckman-Coulter Ostase Access, IDS iSYS Ostase, IDS Ostase enzyme immunoassay, DiaSorin Liaison Ostase and Quidel MicroVue BAP). RESULTS: We observed a high correlation between all the assays ranging from 0.9948 (IDS iSYS vs. IDS EIA) to 0.9215 (DiaSorin Liaison vs. Quidel MicroVue). However, using the regression equations, the equivalent concentration of a Beckman-Coulter Access value of 10μg/L can range from 7.7 to 14.4μg/L and of 20μg/L can range from 16.9 to 27.9μg/L with other assays. According to Beckman-Coulter Access, 13%, 50% and 37% of the patients presented BAP values ≤10, between 10 and 20 and ≥20μg/L, respectively. Discrepancies are observed when other assays are used (concordance from 10 to 100%). CONCLUSIONS: Analytical problems leading to inter-method variation should be overcome to improve the usefulness of this marker in clinical practice. According to correlation results, recalibration of BAP assays is necessary but should not be a major issue. [less ▲]

Detailed reference viewed: 56 (21 ULiège)
Full Text
Peer Reviewed
See detailAnalytical evaluation of the new Abbott Architect 25-OH vitamin D assay
CAVALIER, Etienne ULiege; CARLISI, Ignazia ULiege; BEKAERT, Anne-Catherine ULiege et al

in Clinical Biochemistry (2012), 45

Objectives: Validation of the Architect 25-OH vitamin D assay. Design and methods: Determination of repeatability, reproducibility, accuracy profile and 25(OH)-vitamin D2 recovery on native samples ... [more ▼]

Objectives: Validation of the Architect 25-OH vitamin D assay. Design and methods: Determination of repeatability, reproducibility, accuracy profile and 25(OH)-vitamin D2 recovery on native samples. Comparison with DiaSorin Liaison and RIA. Results and conclusion: Coefficients of variation: b6% (13.6 ng/mL) and 2.2% (78.1 ng/mL). Functional sensitivity: 5 ng/mL. Accuracy profile shows that the method is validated between 13.6 and 78.1 ng/mL. Recovery of 25(OH)D2: 75,8%( 95% CI: 61.9–89.7%). Good correlation with DiaSorin RIA and Liaison b50 ng/mL; above this threshold a systematic positive bias was observed. [less ▲]

Detailed reference viewed: 98 (6 ULiège)
Full Text
Peer Reviewed
See detailTumor-induced osteomalacia: The tumor may stay hidden!
van der Rest, Catherine; CAVALIER, Etienne ULiege; KAUX, Jean-François ULiege et al

in Clinical Biochemistry (2011), 44(14-15), 1264-6

We report the case of a patient with severe muscular and articular tenderness that caused almost complete immobility. This subject had severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth ... [more ▼]

We report the case of a patient with severe muscular and articular tenderness that caused almost complete immobility. This subject had severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth factor 23 (FGF-23) was abnormally high and the diagnostic of tumor-induced osteomalacia was made. Despite multiple tests, the tumor was not localized. In this report, we discuss different possible investigations to localize the tumor. Lastly, we review the potential therapy available when tumor is not found and can thus not be excised. [less ▲]

Detailed reference viewed: 60 (17 ULiège)
Full Text
Peer Reviewed
See detailProteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
Meuwis, Marie-Alice ULiege; Fillet, Marianne ULiege; Lutteri, Laurence ULiege et al

in Clinical Biochemistry (2008), 41(12), 960-7

OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict ... [more ▼]

OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict response in Crohn's disease (CD) patient subcategories, none widely predicting response to infliximab. DESIGN AND METHODS: Twenty CD patients showing clinical response or non response to infliximab were used for serum proteomic profiling on Surface Enhanced Lazer Desorption Ionisation-Time of Flight-Mass Spectrometry (SELDI-TOF-MS), each before and after treatment. Univariate and multivariate data analysis were performed for prediction and characterization of response to infliximab. RESULTS: We obtained a model of classification predicting response to treatment and selected relevant potential biomarkers, among which platelet aggregation factor 4 (PF4). We quantified PF4, sCD40L and IL-6 by ELISA for correlation studies. CONCLUSIONS: This first proteomic pilot study on response to infliximab in CD suggests association between platelet metabolism and response to infliximab and requires validation studies on a larger cohort of patients. [less ▲]

Detailed reference viewed: 158 (26 ULiège)
Full Text
Peer Reviewed
See detailMeasurement uncertainty of creatinine in low values: Another good reason not to use the MDRD formula with low creatinine values
Cavalier, Etienne ULiege; Delanaye, Pierre ULiege; Ferir, Anne-Marie et al

in Clinical Biochemistry (2007), 40(3-4), 285-286

Detailed reference viewed: 53 (2 ULiège)
Full Text
Peer Reviewed
See detailMulticenter evaluation of analytical performance of the Liaison((R)) troponin I assay
Pagani, F.; Stefini, F.; Chapelle, Jean-Paul ULiege et al

in Clinical Biochemistry (2004), 37(9), 750-757

Objectives: This study evaluated the analytical characteristics of the Liaison(R) immunoassay for cardiac troponin I (cTnI). Design and methods: The protocol consisted of eight sections: evaluation of ... [more ▼]

Objectives: This study evaluated the analytical characteristics of the Liaison(R) immunoassay for cardiac troponin I (cTnI). Design and methods: The protocol consisted of eight sections: evaluation of antibody specificity, linearity, detection limit and imprecision, method comparison, evaluation of endogenous interferents, anticoagulant interference, sample stability, and reference values. Results: The assay equally measured free and complexed cTnI. The minimum detectable cTnI concentration was 0.021 mug/l. The cTnI concentration corresponding to a total CVof 10% was 0.056 mug/l. Linearity of response was demonstrated along the entire dynamic range of the assay. Assay interferences were minimal. cTnI concentrations in serum and heparinized plasma were significantly different. Values in EDTA plasma were on average approximately 5% higher than in matched serum, but this difference was not significant. The 99th percentile cTnI value in healthy subjects was 0.036 mug/l. Conclusions: Being sensitive, specific, and precise, the Liaison(R) cTnI assay meets current requirements to aid in the diagnosis of myocardial necrosis. (C) 2004 The Canadian Society of Clinical Chemists. All rights reserved. [less ▲]

Detailed reference viewed: 14 (1 ULiège)
Peer Reviewed
See detailFast determination of myoglobin in serum using a new radial partition immunoassay
Chapelle, Jean-Paul ULiege; Lemache, K.; el Allaf, M. et al

in Clinical Biochemistry (1994), 27(5), 423-8

Detailed reference viewed: 22 (3 ULiège)